Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Shares of NYSE OGEN opened at $0.27 on Wednesday. Oragenics has a 1 year low of $0.25 and a 1 year high of $7.74. The stock has a market capitalization of $3.35 million, a P/E ratio of -0.04 and a beta of 0.49. The company’s 50-day moving average is $0.36 and its 200 day moving average is $1.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC bought a new stake in Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent filing with the Securities & Exchange Commission. 18.71% of the stock is owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.